NASDAQ: VRCA Verrica Pharmaceuticals Inc. 8-K

Verrica shareholders approve amended equity plan, elect two directors at annual meeting

Filed June 9, 2026 · Period ending June 5, 2026 · ~1 min read

Key Changes

  • medium

    Shareholders approved the amended 2018 Equity Incentive Plan with 96% support (11.1M for vs 434K against), governing future stock-based compensation for employees and directors.

    Item 5.07: Annual Meeting Results verify on EDGAR →
  • low

    Paul B. Manning and Lawrence Eichenfield re-elected to board with terms through 2029, receiving over 99% approval with minimal votes withheld.

    Item 5.07: Director Elections verify on EDGAR →
  • low

    Executive compensation received 99.7% advisory approval (11.6M for vs 34K against), indicating strong shareholder support for pay practices.

    Item 5.07: Say-on-Pay Vote verify on EDGAR →

1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (HOTH 10-Q) is open in full — no account needed.

Partner

Trade VRCA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 10, 2026 6:35 PM